AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

Calandra, Gary B.; McCarty, John M.; McGuirk, Joseph P.; Tricot, Guido; Sa, Crocker; Badel, Karin; Grove, Brandon S.; A, Dye; Bridger, Gary

doi:10.1038/sj.bmt.1705908

Cited by 264 publications

(264 citation statements)

References 20 publications

Supporting

Mentioning

245

Contrasting

Unclassified

Order By: Relevance

“…It was suggested that plerixafor might be used in combination with granulocyte-colony stimulating factor (G-CSF) in patients with myeloma or lymphoma in whom an initial mobilization regimen either was predicted to fail or had failed already. The reports on the outcomes of this program revealed that a very reproducible proportion of patients were mobilized successfully with plerixafor (63-75%) [2][3][4][5][6]. However, it was clear that, in a subset of patients, mobilization could not be rescued successfully with plerixafor.…”

Section: Introductionmentioning

confidence: 99%

Identification of prognostic factors for plerixafor‐based hematopoietic stem cell mobilization

et al. 2011

View full text Add to dashboard Cite

The introduction of plerixafor has enabled successful collection of stem cells in the majority of patients with lymphoma or myeloma in whom previous attempts at mobilization have failed. However, a proportion of patients have been shown to be resistant to this mobilization regimen. To identify the factors that impair stem cell mobilization and collection with plerixafor, we reviewed the data for 197 patients who had undergone mobilization with plerixafor and granulocyte-colony stimulating factor in Central Europe. Predictors of mobilization failure were evaluated using logistic regression analysis. Among the 197 patients mobilized, the target of 2.0 3 10 6 CD341 cells/kg was collected from 133 (67.5%). Our analysis revealed that previous treatment with lenalidomide, bortezomib, melphalan, radiotherapy, or autologous stem cell transplantation and regimen of plerixafor use in combination with chemotherapy had no significant effect on the efficiency of collection. In contrast, an age 65 years (odds ratio 0.331, 95% CI: 0.112-0.977, P < 0.05), a diagnosis of non-Hodgkin's lymphoma (odds ratio 0.277, 95% CI: 0.124-0.622, P < 0.01), and treatment with four chemotherapy regimens (odds ratio 0.366, 95% CI: 0.167-0.799, P < 0.05) were associated significantly with failed mobilization. The rate of successful mobilizations was decreased in patients treated with purine analogues (odds ratio 0.323, 95% CI: 0.096-1.094, P 5 0.07) but increased in female patients (odds ratio 1.961, CI: 0.943-4.080, P 5 0.07). Patients who are characterized by the above negative features could benefit potentially from further improvement in the mobilization strategy. Am. J. Hematol. 86:550-553, 2011. V

show abstract

Section: Introductionmentioning

confidence: 99%

Identification of prognostic factors for plerixafor‐based hematopoietic stem cell mobilization

et al. 2011

View full text Add to dashboard Cite

show abstract

“…139 In patients in whom mobilization with G-CSF either alone or in combination with chemotherapy has previously failed, CD34 þ cell yields have been noted to increase by 5-to 100-fold in response to administration of plerixafor plus G-CSF. 139,140 A cohort of 115 patients termed poor mobilizers who received plerixafor as part of a compassionate use protocol was assessed by Calandra et al 140 Collections of X2 Â 10 6 CD34 þ cells/kg after administration of plerixafor plus G-CSF for mobilization were achieved in 60.3% of patients with NHL, 71.4% of patients with MM and 76.5% of patients with HD; these rates were similar for patients who had previously failed mobilization with chemotherapy plus cytokines or cytokines alone. 140 Preliminary results of two phase 3 multicenter randomized placebo-controlled studies indicated that the addition of plerixafor to a G-CSF regimen resulted in greater efficacy than was seen with a regimen of G-CSF alone.…”

Section: Novel Agentsmentioning

confidence: 99%

“…143 The high success rate seen with plerixafor and G-CSF in patients with NHL in whom initial mobilization with G-CSF alone had failed is consistent with results from the compassionate use protocol. 140 SB-251353 SB-251353 is another investigational mobilization agent currently in preclinical studies. 32,33 SB-251353 is an analog of GRO-b, a human CXC chemokine involved in directing the movement of stem cells and leukocytes.…”

Section: Novel Agentsmentioning

confidence: 99%

Improving stem cell mobilization strategies: future directions

Bensinger

DiPersio

McCarty

2009

Bone Marrow Transplant

202

209

View full text Add to dashboard Cite

“…[32][33][34][35] In addition, several studies reported the use of plerixafor in poorly mobilizing patients, with a success rate ranging from 66 to 85% in small-to medium-sized patient groups. [9][10][11][12] On the basis of these findings, plerixafor is being used more widely in clinical practice. 36,37 Nevertheless, no direct comparison data between plerixafor and ancestim are currently available in poorly mobilizing patients.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, plerixafor, formerly known as AMD-3100, was shown to be useful in association with G-CSF for a proportion of poorly mobilizing patients. [9][10][11][12] Recombinant human SCF (rhSCF) or ancestim has also been used in this patient subset.…”

Section: Introductionmentioning

confidence: 99%

Ancestim (r-metHuSCF) plus filgrastim and/or chemotherapy for mobilization of blood progenitors in 513 poorly mobilizing cancer patients: the French compassionate experience

Lapierre

Heshmati

et al. 2010

Bone Marrow Transplant

View full text Add to dashboard Cite

Ancestim (r-MetHuSCF) is available in France for compassionate use in patients who are candidates for high-dose chemotherapy and autologous transplantation, and who failed in previous attempts at mobilization and collection. We report here data from 513 adult patients who benefited from this program, between January 1998 and July 2007. Given with systematic premedication, ancestim was generally well tolerated, although severe but not life-threatening adverse events were reported in 12 individuals. Overall, a graft was obtained or completed for 235 patients (46%). The median number of collected CD34 þ cells was 3.00 Â 10 6 /kg (range: 0.03-39.50). The target threshold of 2 Â 10 6 CD34 þ cells/kg was reached in 161 patients (31%). Factors associated with collection were diagnosis of myeloma, no previous autologous transplant, no more than one previous failed attempt and a mobilization regimen including cytotoxic agents. A total of 207 patients (40%) proceeded to high-dose chemotherapy and autologous transplantation. The median time to reach 0.5 Â 10 9 /L neutrophils and 20 Â 10 9 /L platelets was 12 (6-40) and 13 (0-31) days, respectively. We conclude that a combination of ancestim with filgrastim successfully mobilized CD34 þ cells in peripheral blood, and allowed adequate collection in preparation for autologous transplantation in approximately one-third of poorly mobilizing patients.

show abstract

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

Cited by 264 publications

References 20 publications

Identification of prognostic factors for plerixafor‐based hematopoietic stem cell mobilization

Identification of prognostic factors for plerixafor‐based hematopoietic stem cell mobilization

Improving stem cell mobilization strategies: future directions

Ancestim (r-metHuSCF) plus filgrastim and/or chemotherapy for mobilization of blood progenitors in 513 poorly mobilizing cancer patients: the French compassionate experience

Contact Info

Product

Resources

About